[P02BB01, trichlorfon, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Metrifonate.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AL01, sulpiride, Ipratropium may increase the anticholinergic activities of Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DA01, tacrine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Tacrine.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC03, terbutaline, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Terbutaline.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AE05, lurasidone, Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AD10, dronabinol, The risk or severity of Tachycardia and drowsiness can be increased when Ipratropium is combined with Dronabinol.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[L04AX02, thalidomide, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[L01AC01, thiotepa, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, Thiopental may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AC02, thioridazine, Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[B02AB01, aprotinin, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Aprotinin.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Tilidine.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX02, tramadol, The risk or severity of adverse effects can be increased when Tramadol is combined with Ipratropium.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX05, trazodone, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA06, trichlormethiazide, The serum concentration of Trichlormethiazide can be increased when it is combined with Ipratropium.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Mepenzolate is combined with Ipratropium.]
[S01EB04, demecarium, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Demecarium.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Ipratropium.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Ipratropium.]
[A03AA05, trimebutine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Ipratropium.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AC02, trimethadione, Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Ipratropium is combined with Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Ipratropium.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Tropicamide.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01AA05, tyrothricin, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Tyrothricin.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC18, indacaterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Indacaterol.]
[N06AX09, viloxazine, Viloxazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AF05, zuclopenthixol, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ipratropium.]
[G04BD07, tolterodine, The risk or severity of adverse effects can be increased when Tolterodine is combined with Ipratropium.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01FA01, atropine, The risk or severity of adverse effects can be increased when Atropine is combined with Ipratropium.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Ipratropium is combined with Mirabegron.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Ipratropium.]
[C01CA18, octopamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Octopamine.]
[N05CA04, barbital, Barbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BD02, rasagiline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DA02, donepezil, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Thonzylamine is combined with Ipratropium.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Darifenacin is combined with Ipratropium.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA01, bendroflumethiazide, The serum concentration of Bendroflumethiazide can be increased when it is combined with Ipratropium.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AX06, tegaserod, The therapeutic efficacy of Tegaserod can be decreased when used in combination with Ipratropium.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Ipratropium.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Benzatropine is combined with Ipratropium.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA27, droxidopa, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Droxidopa.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A16AA06, betaine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Betaine.]
[C02CC01, bethanidine, The risk or severity of Tachycardia can be increased when Bethanidine is combined with Ipratropium.]
[A03BA03, hyoscyamine, The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Ipratropium.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC19, olodaterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Olodaterol.]
[N03AG01, valproic acid, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Ipratropium is combined with Glycopyrronium.]
[N05CM19, suvorexant, Suvorexant may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CX03, methacholine, Ipratropium may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Ipratropium.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Ipratropium is combined with Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Biperiden is combined with Ipratropium.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Ipratropium.]
[N06AX11, mirtazapine, Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Difemerine is combined with Ipratropium.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Ipratropium is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Ipratropium.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Brompheniramine is combined with Ipratropium.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07BC01, buprenorphine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Buprenorphine.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DA03, rivastigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Rivastigmine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Ipratropium is combined with Butorphanol.]
[S01GX07, azelastine, Azelastine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Ipratropium.]
[R03CC12, bambuterol, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Bambuterol.]
[N02BF02, pregabalin, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BD03, safinamide, Safinamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC17, bitolterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Bitolterol.]
[J05AG03, efavirenz, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Bornaprine is combined with Ipratropium.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA15, butriptyline, Butriptyline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BX04, capsaicin, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Capsaicin.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Ipratropium.]
[N03AF01, carbamazepine, Carbamazepine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Ipratropium.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Camylofin is combined with Ipratropium.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX24, cannabidiol, The risk or severity of Tachycardia and drowsiness can be increased when Ipratropium is combined with Cannabidiol.]
[N03AX17, stiripentol, Stiripentol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Ipratropium.]
[M03BA02, carisoprodol, Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Revefenacin is combined with Ipratropium.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Ipratropium.]
[B01AC23, cilostazol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Cilostazol.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX27, esketamine, Esketamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Ipratropium.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Ipratropium.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BX08, cyclobenzaprine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Ipratropium.]
[N02CC08, lasmiditan, Lasmiditan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Dezocine.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Dihexyverine is combined with Ipratropium.]
[C01CA14, dopexamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Dopexamine.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Ipratropium.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD14, remimazolam, Remimazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07XX04, sodium oxybate, Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX07, oliceridine, The risk or severity of urinary retention, reduced gastrointestinal motility, and constipation can be increased when Ipratropium is combined with Oliceridine.]
[C03AA04, chlorothiazide, The serum concentration of Chlorothiazide can be increased when it is combined with Ipratropium.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ipratropium.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ipratropium.]
[C03BA04, chlorthalidone, The serum concentration of Chlorthalidone can be increased when it is combined with Ipratropium.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX18, vinpocetine, Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Fenozolone.]
[R03CC15, formoterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Formoterol.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[L01XA01, cisplatin, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Cisplatin.]
[N06AB04, citalopram, Citalopram may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AA04, clemastine, Clemastine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC13, clenbuterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, St. John's Wort may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA04, clomipramine, Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01EA04, clonidine, Clonidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AA01, ondansetron, Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AA02, granisetron, Granisetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH02, clozapine, The risk or severity of adverse effects can be increased when Clozapine is combined with Ipratropium.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S02DA02, cocaine, The risk or severity of adverse effects can be increased when Cocaine is combined with Ipratropium.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Hexocyclium is combined with Ipratropium.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Homatropine.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Ipratropium.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AA03, tropisetron, Tropisetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[H01AX01, pegvisomant, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Pegvisomant.]
[A03AX10, isometheptene, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Isometheptene.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Ipratropium.]
[N03AX09, lamotrigine, The risk or severity of adverse effects can be increased when Lamotrigine is combined with Ipratropium.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07BC04, lofexidine, Lofexidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AX13, loratadine, Ipratropium may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Ipratropium.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Mebeverine is combined with Ipratropium.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Mefenorex.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Adenosine.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Ipratropium.]
[R03CB02, methoxyphenamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Methoxyphenamine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD03, metylperon, Melperone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA07, cyclopenthiazide, The serum concentration of Cyclopenthiazide can be increased when it is combined with Ipratropium.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Ipratropium is combined with Cyclopentolate.]
[N06AX07, minaprine, Minaprine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AG02, moclobemide, Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AX02, cyproheptadine, The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ipratropium.]
[C02AC05, moxonidine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Moxonidine.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AD11, nabilone, The risk or severity of Tachycardia and drowsiness can be increased when Ipratropium is combined with Nabilone.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX06, nefazodone, Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA05, norfenefrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Escitalopram is combined with Ipratropium.]
[G04BD08, solifenacin, The risk or severity of adverse effects can be increased when Solifenacin is combined with Ipratropium.]
[N06AA01, desipramine, The risk or severity of adverse effects can be increased when Desipramine is combined with Ipratropium.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Dexetimide is combined with Ipratropium.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Ipratropium.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Ipratropium.]
[N06BA02, dextroamphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Ipratropium.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Paroxetine is combined with Ipratropium.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Ipratropium is combined with Diamorphine.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Dicyclomine is combined with Ipratropium.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Pipenzolate is combined with Ipratropium.]
[R03CC07, pirbuterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Pirbuterol.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Poldine is combined with Ipratropium.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Hydromorphone.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Dimetindene is combined with Ipratropium.]
[R03CC08, procaterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Procaterol.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AA02, diphenhydramine, The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ipratropium.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Ipratropium is combined with Diphenoxylate.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03FA02, cisapride, Cisapride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC14, reproterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Reproterol.]
[C01BA03, disopyramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Ipratropium.]
[N07AA03, distigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Distigmine.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AX08, risperidone, Risperidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC12, salmeterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Dobutamine.]
[A03FA03, domperidone, The therapeutic efficacy of Domperidone can be decreased when used in combination with Ipratropium.]
[C01CA04, dopamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of adverse effects can be increased when Dosulepin is combined with Ipratropium.]
[N06AA12, doxepin, The risk or severity of adverse effects can be increased when Doxepin is combined with Ipratropium.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Ipratropium.]
[R06AA09, doxylamine, The risk or severity of adverse effects can be increased when Doxylamine is combined with Ipratropium.]
[N06AB06, sertraline, Sertraline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A08AA10, sibutramine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Ipratropium.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Ipratropium.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CX07, edrophonium, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Edrophonium.]
[S01GA02, tetrahydrozoline, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Tetryzoline.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Emepronium is combined with Ipratropium.]
[N06AX14, tianeptine, Tianeptine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AG03, toloxatone, Toloxatone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BA09, atomoxetine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Ipratropium.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Ipratropium is combined with Topiramate.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Tramazoline.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Ipratropium.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Tropatepine is combined with Ipratropium.]
[R03CC11, tulobuterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Tulobuterol.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01FB02, ephedrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Ephedrine.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX16, venlafaxine, Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CX07, xamoterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Xamoterol.]
[S01EA01, epinephrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Epinephrine.]
[N05CF02, zolpidem, Zolpidem may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX15, zonisamide, Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01BG01, moricizine, Moricizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G02AB03, ergonovine, Ergometrine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CA02, ergotamine, Ergotamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA15, gepefrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Gepefrine.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Ipratropium.]
[N03AD01, ethosuximide, Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Etilefrine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A02BA04, nizatidine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Nizatidine.]
[R06AX12, terfenadine, The risk or severity of adverse effects can be increased when Terfenadine is combined with Ipratropium.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AB08, fluvoxamine, Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX26, fenfluramine, Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Ipratropium is combined with Fentanyl.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Flavoxate is combined with Ipratropium.]
[N07CA03, flunarizine, Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA14, melitracen, Melitracen may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V03AZ01, ethanol, Ethanol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AB03, fluoxetine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AF01, flupenthixol, The risk or severity of adverse effects can be increased when Flupentixol is combined with Ipratropium.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AG01, fluspirilene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX17, adrafinil, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Adrafinil.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G01AX06, furazolidone, Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CF04, eszopiclone, Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AL05, amisulpride, Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DA04, galantamine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Galantamine.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA04, barbexaclone, Barbexaclone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BC06, cabergoline, Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AD03, methsuximide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Ipratropium is combined with Alfentanil.]
[H04AA01, glucagon, Ipratropium may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Ipratropium.]
[N05AD01, haloperidol, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Quetiapine is combined with Ipratropium.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Ipratropium.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Ipratropium.]
[N05CA16, hexobarbital, Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC05, hexoprenaline, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Hexoprenaline.]
[C03AA03, hydrochlorothiazide, The serum concentration of Hydrochlorothiazide can be increased when it is combined with Ipratropium.]
[R05DA03, hydrocodone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Hydrocodone.]
[C03AA02, hydroflumethiazide, The serum concentration of Hydroflumethiazide can be increased when it is combined with Ipratropium.]
[G04BD06, propiverine, The risk or severity of adverse effects can be increased when Propiverine is combined with Ipratropium.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02AC06, rilmenidine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Rilmenidine.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Ipratropium.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Ipratropium is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of adverse effects can be increased when Imipramine is combined with Ipratropium.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03BA11, indapamide, The serum concentration of Indapamide can be increased when it is combined with Ipratropium.]
[N06AX17, milnacipran, Milnacipran may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Piperidolate is combined with Ipratropium.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AE01, buclizine, The risk or severity of adverse effects can be increased when Buclizine is combined with Ipratropium.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Anagrelide is combined with Ipratropium.]
[C07AA01, alprenolol, Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03BA02, quinethazone, The serum concentration of Quinethazone can be increased when it is combined with Ipratropium.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AF05, iproniazid, Iproniazid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC06, isoetharine, The risk or severity of Tachycardia can be increased when Isoetharine is combined with Ipratropium.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01EB07, isoflurophate, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CB01, isoproterenol, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Isoprenaline.]
[C04AA01, isoxsuprine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Isoxsuprine.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Ipratropium.]
[C01CA22, arbutamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Arbutamine.]
[N04BC09, rotigotine, Rotigotine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C07AG01, labetalol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Amantadine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Ipratropium.]
[N07AA30, ambenonium, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ipratropium.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BA01, levodopa, The absorption of Levodopa can be decreased when combined with Ipratropium.]
[S02DA01, lidocaine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH01, loxapine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Loxapine.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Ipratropium.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Ipratropium.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA21, maprotiline, The risk or severity of adverse effects can be increased when Maprotiline is combined with Ipratropium.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Mecamylamine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Ipratropium.]
[P01BC02, mefloquine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DX01, memantine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Mephentermine.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Ipratropium is combined with Meptazinol.]
[N05AC03, mesoridazine, Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AX13, paliperidone, Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA09, metaraminol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Metaraminol.]
[A04AA04, dolasetron, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Methadone.]
[N06BA03, methamphetamine, Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Methantheline is combined with Ipratropium.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA15, methohexital, Methohexital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02BG08, ziconotide, Ziconotide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA02, methotrimeprazine, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ipratropium.]
[C01CA10, methoxamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Methoxamine.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA08, methyclothiazide, The serum concentration of Methyclothiazide can be increased when it is combined with Ipratropium.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Ipratropium.]
[V04CG05, methylene blue, Methylene blue may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AF03, rufinamide, Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Ipratropium.]
[C03BA08, metolazone, The serum concentration of Metolazone can be increased when it is combined with Ipratropium.]
[N06AX03, mianserin, Mianserin may increase the anticholinergic activities of Ipratropium.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA17, midodrine, The risk or severity of Tachycardia can be increased when Midodrine is combined with Ipratropium.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Ipratropium.]
[N06BA12, lisdexamfetamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Lisdexamfetamine.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA09, amitriptyline, The risk or severity of adverse effects can be increased when Amitriptyline is combined with Ipratropium.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Morphine.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA02, amobarbital, Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, The risk or severity of adverse effects can be increased when Amoxapine is combined with Ipratropium.]
[N03AB05, fosphenytoin, Fosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Nalbuphine.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Naltrexone.]
[S01GA01, naphazoline, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Ipratropium.]
[N06AX21, duloxetine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Ipratropium is combined with Remifentanil.]
[S01EB06, neostigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AF02, nialamide, Nialamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Nicardipine is combined with Ipratropium.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Ipratropium.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA03, norepinephrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Norepinephrine.]
[N06AA10, nortriptyline, The risk or severity of adverse effects can be increased when Nortriptyline is combined with Ipratropium.]
[G02CA02, nylidrin, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Nylidrin.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Ipratropium is combined with Opium.]
[R03CB03, metaproterenol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Orciprenaline.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C07AA02, oxprenolol, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The absorption of Ipratropium can be decreased when combined with Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Oxymorphone.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Ipratropium.]
[N05AH05, asenapine, Asenapine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX06, tapentadol, The risk or severity of adverse effects can be increased when Ipratropium is combined with Tapentadol.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Ipratropium.]
[N05CC05, paraldehyde, Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02KC01, pargyline, Pargyline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Fesoterodine is combined with Ipratropium.]
[C07AA23, penbutolol, Penbutolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AG03, penfluridol, Penfluridol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Pentazocine.]
[N05CA01, pentobarbital, Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BC02, pergolide, Pergolide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Phenazocine.]
[N06AF03, phenelzine, Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA02, phenobarbital, Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Ipratropium.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Phenoperidine.]
[A08AA01, phentermine, The risk or severity of Tachycardia can be increased when Phentermine is combined with Ipratropium.]
[S01GA05, phenylephrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Phenylephrine.]
[R01BA01, phenylpropanolamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Phenylpropanolamine.]
[N03AB02, phenytoin, Phenytoin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V03AB19, physostigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Physostigmine.]
[N05AG02, pimozide, Pimozide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C07AA03, pindolol, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Pirenzepine is combined with Ipratropium.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Piritramide.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Pizotifen is combined with Ipratropium.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ipratropium.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA05, polythiazide, The serum concentration of Polythiazide can be increased when it is combined with Ipratropium.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Ipratropium is combined with Potassium chloride.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA03, primidone, Primidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01BA02, procainamide, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Procainamide.]
[S01HA05, procaine, Procaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[L01XB01, procarbazine, Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Ipratropium.]
[N05AA03, promazine, The risk or severity of adverse effects can be increased when Promazine is combined with Ipratropium.]
[R06AD02, promethazine, The risk or severity of adverse effects can be increased when Promethazine is combined with Ipratropium.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Propantheline is combined with Ipratropium.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Ipratropium.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Ipratropium is combined with Dextropropoxyphene.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R01BA02, pseudoephedrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ipratropium.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Diphemanil is combined with Ipratropium.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Isopropamide is combined with Ipratropium.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Methscopolamine is combined with Ipratropium.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01BA01, quinidine, The risk or severity of adverse effects can be increased when Quinidine is combined with Ipratropium.]
[P01BC01, quinine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC05, rimiterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Ritodrine.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Ipratropium.]
[N05CA06, secobarbital, Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Ipratropium.]
[N04BD01, selegiline, Selegiline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Ipratropium.]
[P02BB01, trichlorfon, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Metrifonate.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AL01, sulpiride, Ipratropium may increase the anticholinergic activities of Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DA01, tacrine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Tacrine.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC03, terbutaline, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Terbutaline.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AE05, lurasidone, Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AD10, dronabinol, The risk or severity of Tachycardia and drowsiness can be increased when Ipratropium is combined with Dronabinol.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[L04AX02, thalidomide, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[L01AC01, thiotepa, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, Thiopental may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AC02, thioridazine, Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[B02AB01, aprotinin, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Aprotinin.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Tilidine.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX02, tramadol, The risk or severity of adverse effects can be increased when Tramadol is combined with Ipratropium.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX05, trazodone, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA06, trichlormethiazide, The serum concentration of Trichlormethiazide can be increased when it is combined with Ipratropium.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Mepenzolate is combined with Ipratropium.]
[S01EB04, demecarium, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Demecarium.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Ipratropium.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Ipratropium.]
[A03AA05, trimebutine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Ipratropium.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AC02, trimethadione, Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Ipratropium is combined with Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Ipratropium.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Tropicamide.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01AA05, tyrothricin, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Tyrothricin.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC18, indacaterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Indacaterol.]
[N06AX09, viloxazine, Viloxazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AF05, zuclopenthixol, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ipratropium.]
[G04BD07, tolterodine, The risk or severity of adverse effects can be increased when Tolterodine is combined with Ipratropium.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01FA01, atropine, The risk or severity of adverse effects can be increased when Atropine is combined with Ipratropium.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Ipratropium is combined with Mirabegron.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Ipratropium.]
[C01CA18, octopamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Octopamine.]
[N05CA04, barbital, Barbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BD02, rasagiline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DA02, donepezil, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Thonzylamine is combined with Ipratropium.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Darifenacin is combined with Ipratropium.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA01, bendroflumethiazide, The serum concentration of Bendroflumethiazide can be increased when it is combined with Ipratropium.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AX06, tegaserod, The therapeutic efficacy of Tegaserod can be decreased when used in combination with Ipratropium.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Ipratropium.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Benzatropine is combined with Ipratropium.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA27, droxidopa, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Droxidopa.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A16AA06, betaine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Betaine.]
[C02CC01, bethanidine, The risk or severity of Tachycardia can be increased when Bethanidine is combined with Ipratropium.]
[A03BA03, hyoscyamine, The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Ipratropium.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC19, olodaterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Olodaterol.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Ipratropium is combined with Glycopyrronium.]
[N05CM19, suvorexant, Suvorexant may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CX03, methacholine, Ipratropium may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Ipratropium.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Ipratropium is combined with Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Biperiden is combined with Ipratropium.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Ipratropium.]
[N06AX11, mirtazapine, Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Difemerine is combined with Ipratropium.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Ipratropium is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Ipratropium.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Brompheniramine is combined with Ipratropium.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07BC01, buprenorphine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Buprenorphine.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DA03, rivastigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Rivastigmine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Ipratropium is combined with Butorphanol.]
[S01GX07, azelastine, Azelastine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Ipratropium.]
[R03CC12, bambuterol, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Bambuterol.]
[N02BF02, pregabalin, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BD03, safinamide, Safinamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC17, bitolterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Bitolterol.]
[J05AG03, efavirenz, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Bornaprine is combined with Ipratropium.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA15, butriptyline, Butriptyline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BX04, capsaicin, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Capsaicin.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Ipratropium.]
[N03AF01, carbamazepine, Carbamazepine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Ipratropium.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Camylofin is combined with Ipratropium.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AG01, valproic acid, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX24, cannabidiol, The risk or severity of Tachycardia and drowsiness can be increased when Ipratropium is combined with Cannabidiol.]
[N03AX17, stiripentol, Stiripentol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Ipratropium.]
[M03BA02, carisoprodol, Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Revefenacin is combined with Ipratropium.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Ipratropium.]
[B01AC23, cilostazol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Cilostazol.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX27, esketamine, Esketamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Ipratropium.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Ipratropium.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BX08, cyclobenzaprine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Ipratropium.]
[N02CC08, lasmiditan, Lasmiditan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Dezocine.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Dihexyverine is combined with Ipratropium.]
[C01CA14, dopexamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Dopexamine.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Ipratropium.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD14, remimazolam, Remimazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07XX04, sodium oxybate, Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX07, oliceridine, The risk or severity of urinary retention, reduced gastrointestinal motility, and constipation can be increased when Ipratropium is combined with Oliceridine.]
[C03AA04, chlorothiazide, The serum concentration of Chlorothiazide can be increased when it is combined with Ipratropium.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ipratropium.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ipratropium.]
[C03BA04, chlorthalidone, The serum concentration of Chlorthalidone can be increased when it is combined with Ipratropium.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX18, vinpocetine, Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Fenozolone.]
[R03CC15, formoterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Formoterol.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[L01XA01, cisplatin, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Cisplatin.]
[N06AB04, citalopram, Citalopram may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AA04, clemastine, Clemastine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC13, clenbuterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, St. John's Wort may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA04, clomipramine, Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01EA04, clonidine, Clonidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AA01, ondansetron, Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AA02, granisetron, Granisetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH02, clozapine, The risk or severity of adverse effects can be increased when Clozapine is combined with Ipratropium.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S02DA02, cocaine, The risk or severity of adverse effects can be increased when Cocaine is combined with Ipratropium.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Hexocyclium is combined with Ipratropium.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Homatropine.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Ipratropium.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AA03, tropisetron, Tropisetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[H01AX01, pegvisomant, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Pegvisomant.]
[A03AX10, isometheptene, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Isometheptene.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Ipratropium.]
[N03AX09, lamotrigine, The risk or severity of adverse effects can be increased when Lamotrigine is combined with Ipratropium.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07BC04, lofexidine, Lofexidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AX13, loratadine, Ipratropium may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Ipratropium.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Mebeverine is combined with Ipratropium.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Mefenorex.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Adenosine.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Ipratropium.]
[R03CB02, methoxyphenamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Methoxyphenamine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD03, metylperon, Melperone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA07, cyclopenthiazide, The serum concentration of Cyclopenthiazide can be increased when it is combined with Ipratropium.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Ipratropium is combined with Cyclopentolate.]
[N06AX07, minaprine, Minaprine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AG02, moclobemide, Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AX02, cyproheptadine, The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ipratropium.]
[C02AC05, moxonidine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Moxonidine.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AD11, nabilone, The risk or severity of Tachycardia and drowsiness can be increased when Ipratropium is combined with Nabilone.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX06, nefazodone, Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA05, norfenefrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Escitalopram is combined with Ipratropium.]
[G04BD08, solifenacin, The risk or severity of adverse effects can be increased when Solifenacin is combined with Ipratropium.]
[N06AA01, desipramine, The risk or severity of adverse effects can be increased when Desipramine is combined with Ipratropium.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Dexetimide is combined with Ipratropium.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Ipratropium.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Ipratropium.]
[N06BA02, dextroamphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Ipratropium.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Paroxetine is combined with Ipratropium.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Ipratropium is combined with Diamorphine.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Dicyclomine is combined with Ipratropium.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Pipenzolate is combined with Ipratropium.]
[R03CC07, pirbuterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Pirbuterol.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Poldine is combined with Ipratropium.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Hydromorphone.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Dimetindene is combined with Ipratropium.]
[R03CC08, procaterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Procaterol.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AA02, diphenhydramine, The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ipratropium.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Ipratropium is combined with Diphenoxylate.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03FA02, cisapride, Cisapride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC14, reproterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Reproterol.]
[C01BA03, disopyramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Ipratropium.]
[N07AA03, distigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Distigmine.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AX08, risperidone, Risperidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC12, salmeterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Dobutamine.]
[A03FA03, domperidone, The therapeutic efficacy of Domperidone can be decreased when used in combination with Ipratropium.]
[C01CA04, dopamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of adverse effects can be increased when Dosulepin is combined with Ipratropium.]
[N06AA12, doxepin, The risk or severity of adverse effects can be increased when Doxepin is combined with Ipratropium.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Ipratropium.]
[R06AA09, doxylamine, The risk or severity of adverse effects can be increased when Doxylamine is combined with Ipratropium.]
[N06AB06, sertraline, Sertraline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A08AA10, sibutramine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Ipratropium.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Ipratropium.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CX07, edrophonium, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Edrophonium.]
[S01GA02, tetrahydrozoline, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Tetryzoline.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Emepronium is combined with Ipratropium.]
[N06AX14, tianeptine, Tianeptine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AG03, toloxatone, Toloxatone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BA09, atomoxetine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Ipratropium.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Ipratropium is combined with Topiramate.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Tramazoline.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Ipratropium.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Tropatepine is combined with Ipratropium.]
[R03CC11, tulobuterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Tulobuterol.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01FB02, ephedrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Ephedrine.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX16, venlafaxine, Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CX07, xamoterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Xamoterol.]
[S01EA01, epinephrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Epinephrine.]
[N05CF02, zolpidem, Zolpidem may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX15, zonisamide, Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01BG01, moricizine, Moricizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G02AB03, ergonovine, Ergometrine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CA02, ergotamine, Ergotamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA15, gepefrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Gepefrine.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Ipratropium.]
[N03AD01, ethosuximide, Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Etilefrine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A02BA04, nizatidine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Nizatidine.]
[R06AX12, terfenadine, The risk or severity of adverse effects can be increased when Terfenadine is combined with Ipratropium.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AB08, fluvoxamine, Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX26, fenfluramine, Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Ipratropium is combined with Fentanyl.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Flavoxate is combined with Ipratropium.]
[N07CA03, flunarizine, Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA14, melitracen, Melitracen may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V03AZ01, ethanol, Ethanol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AB03, fluoxetine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AF01, flupenthixol, The risk or severity of adverse effects can be increased when Flupentixol is combined with Ipratropium.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AG01, fluspirilene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX17, adrafinil, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Adrafinil.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G01AX06, furazolidone, Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CF04, eszopiclone, Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AL05, amisulpride, Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DA04, galantamine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Galantamine.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA04, barbexaclone, Barbexaclone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BC06, cabergoline, Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AD03, methsuximide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Ipratropium is combined with Alfentanil.]
[H04AA01, glucagon, Ipratropium may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Ipratropium.]
[N05AD01, haloperidol, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Quetiapine is combined with Ipratropium.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Ipratropium.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Ipratropium.]
[N05CA16, hexobarbital, Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC05, hexoprenaline, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Hexoprenaline.]
[C03AA03, hydrochlorothiazide, The serum concentration of Hydrochlorothiazide can be increased when it is combined with Ipratropium.]
[R05DA03, hydrocodone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Hydrocodone.]
[C03AA02, hydroflumethiazide, The serum concentration of Hydroflumethiazide can be increased when it is combined with Ipratropium.]
[G04BD06, propiverine, The risk or severity of adverse effects can be increased when Propiverine is combined with Ipratropium.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02AC06, rilmenidine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Rilmenidine.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Ipratropium.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Ipratropium is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of adverse effects can be increased when Imipramine is combined with Ipratropium.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03BA11, indapamide, The serum concentration of Indapamide can be increased when it is combined with Ipratropium.]
[N06AX17, milnacipran, Milnacipran may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Piperidolate is combined with Ipratropium.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AE01, buclizine, The risk or severity of adverse effects can be increased when Buclizine is combined with Ipratropium.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Anagrelide is combined with Ipratropium.]
[C07AA01, alprenolol, Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03BA02, quinethazone, The serum concentration of Quinethazone can be increased when it is combined with Ipratropium.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AF05, iproniazid, Iproniazid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC06, isoetharine, The risk or severity of Tachycardia can be increased when Isoetharine is combined with Ipratropium.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01EB07, isoflurophate, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CB01, isoproterenol, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Isoprenaline.]
[C04AA01, isoxsuprine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Isoxsuprine.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Ipratropium.]
[C01CA22, arbutamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Arbutamine.]
[N04BC09, rotigotine, Rotigotine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C07AG01, labetalol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Amantadine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Ipratropium.]
[N07AA30, ambenonium, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ipratropium.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BA01, levodopa, The absorption of Levodopa can be decreased when combined with Ipratropium.]
[S02DA01, lidocaine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH01, loxapine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Loxapine.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Ipratropium.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Ipratropium.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA21, maprotiline, The risk or severity of adverse effects can be increased when Maprotiline is combined with Ipratropium.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Mecamylamine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Ipratropium.]
[P01BC02, mefloquine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DX01, memantine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Mephentermine.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Ipratropium is combined with Meptazinol.]
[N05AC03, mesoridazine, Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AX13, paliperidone, Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA09, metaraminol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Metaraminol.]
[A04AA04, dolasetron, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Methadone.]
[N06BA03, methamphetamine, Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Methantheline is combined with Ipratropium.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA15, methohexital, Methohexital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02BG08, ziconotide, Ziconotide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA02, methotrimeprazine, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ipratropium.]
[C01CA10, methoxamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Methoxamine.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA08, methyclothiazide, The serum concentration of Methyclothiazide can be increased when it is combined with Ipratropium.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Ipratropium.]
[V04CG05, methylene blue, Methylene blue may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AF03, rufinamide, Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Ipratropium.]
[C03BA08, metolazone, The serum concentration of Metolazone can be increased when it is combined with Ipratropium.]
[N06AX03, mianserin, Mianserin may increase the anticholinergic activities of Ipratropium.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA17, midodrine, The risk or severity of Tachycardia can be increased when Midodrine is combined with Ipratropium.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Ipratropium.]
[N06BA12, lisdexamfetamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Lisdexamfetamine.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA09, amitriptyline, The risk or severity of adverse effects can be increased when Amitriptyline is combined with Ipratropium.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Morphine.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA02, amobarbital, Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, The risk or severity of adverse effects can be increased when Amoxapine is combined with Ipratropium.]
[N03AB05, fosphenytoin, Fosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Nalbuphine.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Naltrexone.]
[S01GA01, naphazoline, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Ipratropium.]
[N06AX21, duloxetine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Ipratropium is combined with Remifentanil.]
[S01EB06, neostigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AF02, nialamide, Nialamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Nicardipine is combined with Ipratropium.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Ipratropium.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA03, norepinephrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Norepinephrine.]
[N06AA10, nortriptyline, The risk or severity of adverse effects can be increased when Nortriptyline is combined with Ipratropium.]
[G02CA02, nylidrin, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Nylidrin.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Ipratropium is combined with Opium.]
[R03CB03, metaproterenol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Orciprenaline.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C07AA02, oxprenolol, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The absorption of Ipratropium can be decreased when combined with Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Oxymorphone.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Ipratropium.]
[N05AH05, asenapine, Asenapine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX06, tapentadol, The risk or severity of adverse effects can be increased when Ipratropium is combined with Tapentadol.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Ipratropium.]
[N05CC05, paraldehyde, Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02KC01, pargyline, Pargyline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Fesoterodine is combined with Ipratropium.]
[C07AA23, penbutolol, Penbutolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AG03, penfluridol, Penfluridol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Pentazocine.]
[N05CA01, pentobarbital, Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BC02, pergolide, Pergolide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Phenazocine.]
[N06AF03, phenelzine, Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA02, phenobarbital, Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Ipratropium.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Phenoperidine.]
[A08AA01, phentermine, The risk or severity of Tachycardia can be increased when Phentermine is combined with Ipratropium.]
[S01GA05, phenylephrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Phenylephrine.]
[R01BA01, phenylpropanolamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Phenylpropanolamine.]
[N03AB02, phenytoin, Phenytoin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V03AB19, physostigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Physostigmine.]
[N05AG02, pimozide, Pimozide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C07AA03, pindolol, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Pirenzepine is combined with Ipratropium.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Piritramide.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Pizotifen is combined with Ipratropium.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ipratropium.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA05, polythiazide, The serum concentration of Polythiazide can be increased when it is combined with Ipratropium.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Ipratropium is combined with Potassium chloride.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA03, primidone, Primidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01BA02, procainamide, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Procainamide.]
[S01HA05, procaine, Procaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[L01XB01, procarbazine, Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Ipratropium.]
[N05AA03, promazine, The risk or severity of adverse effects can be increased when Promazine is combined with Ipratropium.]
[R06AD02, promethazine, The risk or severity of adverse effects can be increased when Promethazine is combined with Ipratropium.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Propantheline is combined with Ipratropium.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Ipratropium.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Ipratropium is combined with Dextropropoxyphene.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R01BA02, pseudoephedrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ipratropium.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Diphemanil is combined with Ipratropium.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Isopropamide is combined with Ipratropium.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Methscopolamine is combined with Ipratropium.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01BA01, quinidine, The risk or severity of adverse effects can be increased when Quinidine is combined with Ipratropium.]
[P01BC01, quinine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC05, rimiterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Ritodrine.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Ipratropium.]
[N05CA06, secobarbital, Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Ipratropium.]
[N04BD01, selegiline, Selegiline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Ipratropium.]
[P02BB01, trichlorfon, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Metrifonate.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AL01, sulpiride, Ipratropium may increase the anticholinergic activities of Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DA01, tacrine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Tacrine.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC03, terbutaline, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Terbutaline.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AE05, lurasidone, Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AD10, dronabinol, The risk or severity of Tachycardia and drowsiness can be increased when Ipratropium is combined with Dronabinol.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[L04AX02, thalidomide, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[L01AC01, thiotepa, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, Thiopental may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AC02, thioridazine, Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[B02AB01, aprotinin, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Aprotinin.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Tilidine.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX02, tramadol, The risk or severity of adverse effects can be increased when Tramadol is combined with Ipratropium.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX05, trazodone, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA06, trichlormethiazide, The serum concentration of Trichlormethiazide can be increased when it is combined with Ipratropium.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Mepenzolate is combined with Ipratropium.]
[S01EB04, demecarium, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Demecarium.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Ipratropium.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Ipratropium.]
[A03AA05, trimebutine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Ipratropium.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AC02, trimethadione, Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Ipratropium is combined with Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Ipratropium.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Tropicamide.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01AA05, tyrothricin, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Tyrothricin.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC18, indacaterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Indacaterol.]
[N06AX09, viloxazine, Viloxazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AF05, zuclopenthixol, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ipratropium.]
[G04BD07, tolterodine, The risk or severity of adverse effects can be increased when Tolterodine is combined with Ipratropium.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01FA01, atropine, The risk or severity of adverse effects can be increased when Atropine is combined with Ipratropium.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Ipratropium is combined with Mirabegron.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Ipratropium.]
[C01CA18, octopamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Octopamine.]
[N05CA04, barbital, Barbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BD02, rasagiline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DA02, donepezil, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Thonzylamine is combined with Ipratropium.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Darifenacin is combined with Ipratropium.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA01, bendroflumethiazide, The serum concentration of Bendroflumethiazide can be increased when it is combined with Ipratropium.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AX06, tegaserod, The therapeutic efficacy of Tegaserod can be decreased when used in combination with Ipratropium.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Ipratropium.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Benzatropine is combined with Ipratropium.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA27, droxidopa, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Droxidopa.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A16AA06, betaine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Betaine.]
[C02CC01, bethanidine, The risk or severity of Tachycardia can be increased when Bethanidine is combined with Ipratropium.]
[A03BA03, hyoscyamine, The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Ipratropium.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC19, olodaterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Olodaterol.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Ipratropium is combined with Glycopyrronium.]
[N05CM19, suvorexant, Suvorexant may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CX03, methacholine, Ipratropium may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Ipratropium.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Ipratropium is combined with Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Biperiden is combined with Ipratropium.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Ipratropium.]
[N06AX11, mirtazapine, Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Difemerine is combined with Ipratropium.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Ipratropium is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Ipratropium.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Brompheniramine is combined with Ipratropium.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07BC01, buprenorphine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Buprenorphine.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DA03, rivastigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Rivastigmine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Ipratropium is combined with Butorphanol.]
[S01GX07, azelastine, Azelastine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Ipratropium.]
[R03CC12, bambuterol, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Bambuterol.]
[N02BF02, pregabalin, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BD03, safinamide, Safinamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC17, bitolterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Bitolterol.]
[J05AG03, efavirenz, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Bornaprine is combined with Ipratropium.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA15, butriptyline, Butriptyline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BX04, capsaicin, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Capsaicin.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Ipratropium.]
[N03AF01, carbamazepine, Carbamazepine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Ipratropium.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Camylofin is combined with Ipratropium.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX24, cannabidiol, The risk or severity of Tachycardia and drowsiness can be increased when Ipratropium is combined with Cannabidiol.]
[N03AX17, stiripentol, Stiripentol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Ipratropium.]
[M03BA02, carisoprodol, Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Revefenacin is combined with Ipratropium.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Ipratropium.]
[B01AC23, cilostazol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Cilostazol.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX27, esketamine, Esketamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Ipratropium.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Ipratropium.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BX08, cyclobenzaprine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Ipratropium.]
[N02CC08, lasmiditan, Lasmiditan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Dezocine.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Dihexyverine is combined with Ipratropium.]
[C01CA14, dopexamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Dopexamine.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Ipratropium.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD14, remimazolam, Remimazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX07, oliceridine, The risk or severity of urinary retention, reduced gastrointestinal motility, and constipation can be increased when Ipratropium is combined with Oliceridine.]
[C03AA04, chlorothiazide, The serum concentration of Chlorothiazide can be increased when it is combined with Ipratropium.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ipratropium.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ipratropium.]
[C03BA04, chlorthalidone, The serum concentration of Chlorthalidone can be increased when it is combined with Ipratropium.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX18, vinpocetine, Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Fenozolone.]
[R03CC15, formoterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Formoterol.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[L01XA01, cisplatin, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Cisplatin.]
[N06AB04, citalopram, Citalopram may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AA04, clemastine, Clemastine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC13, clenbuterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, St. John's Wort may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA04, clomipramine, Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01EA04, clonidine, Clonidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AA01, ondansetron, Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AA02, granisetron, Granisetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH02, clozapine, The risk or severity of adverse effects can be increased when Clozapine is combined with Ipratropium.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S02DA02, cocaine, The risk or severity of adverse effects can be increased when Cocaine is combined with Ipratropium.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Hexocyclium is combined with Ipratropium.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Homatropine.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Ipratropium.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AA03, tropisetron, Tropisetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[H01AX01, pegvisomant, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Pegvisomant.]
[A03AX10, isometheptene, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Isometheptene.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Ipratropium.]
[N03AX09, lamotrigine, The risk or severity of adverse effects can be increased when Lamotrigine is combined with Ipratropium.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07BC04, lofexidine, Lofexidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AX13, loratadine, Ipratropium may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Ipratropium.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Mebeverine is combined with Ipratropium.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Mefenorex.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Adenosine.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Ipratropium.]
[R03CB02, methoxyphenamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Methoxyphenamine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD03, metylperon, Melperone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA07, cyclopenthiazide, The serum concentration of Cyclopenthiazide can be increased when it is combined with Ipratropium.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Ipratropium is combined with Cyclopentolate.]
[N06AX07, minaprine, Minaprine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AG02, moclobemide, Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AX02, cyproheptadine, The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ipratropium.]
[C02AC05, moxonidine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Moxonidine.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A04AD11, nabilone, The risk or severity of Tachycardia and drowsiness can be increased when Ipratropium is combined with Nabilone.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX06, nefazodone, Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA05, norfenefrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Escitalopram is combined with Ipratropium.]
[G04BD08, solifenacin, The risk or severity of adverse effects can be increased when Solifenacin is combined with Ipratropium.]
[N06AA01, desipramine, The risk or severity of adverse effects can be increased when Desipramine is combined with Ipratropium.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Dexetimide is combined with Ipratropium.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Ipratropium.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Ipratropium.]
[N06BA02, dextroamphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Ipratropium.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Paroxetine is combined with Ipratropium.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Ipratropium is combined with Diamorphine.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Dicyclomine is combined with Ipratropium.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Pipenzolate is combined with Ipratropium.]
[R03CC07, pirbuterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Pirbuterol.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Poldine is combined with Ipratropium.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Hydromorphone.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Dimetindene is combined with Ipratropium.]
[R03CC08, procaterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Procaterol.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AA02, diphenhydramine, The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ipratropium.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Ipratropium is combined with Diphenoxylate.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03FA02, cisapride, Cisapride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC14, reproterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Reproterol.]
[C01BA03, disopyramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Ipratropium.]
[N07AA03, distigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Distigmine.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AX08, risperidone, Risperidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC12, salmeterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Dobutamine.]
[A03FA03, domperidone, The therapeutic efficacy of Domperidone can be decreased when used in combination with Ipratropium.]
[C01CA04, dopamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of adverse effects can be increased when Dosulepin is combined with Ipratropium.]
[N06AA12, doxepin, The risk or severity of adverse effects can be increased when Doxepin is combined with Ipratropium.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Ipratropium.]
[R06AA09, doxylamine, The risk or severity of adverse effects can be increased when Doxylamine is combined with Ipratropium.]
[N06AB06, sertraline, Sertraline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A08AA10, sibutramine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Ipratropium.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Ipratropium.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CX07, edrophonium, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Edrophonium.]
[S01GA02, tetrahydrozoline, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Tetryzoline.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Emepronium is combined with Ipratropium.]
[N06AX14, tianeptine, Tianeptine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AG03, toloxatone, Toloxatone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BA09, atomoxetine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Ipratropium.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Ipratropium is combined with Topiramate.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Tramazoline.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Ipratropium.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Tropatepine is combined with Ipratropium.]
[R03CC11, tulobuterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Tulobuterol.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01FB02, ephedrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Ephedrine.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX16, venlafaxine, Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CX07, xamoterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Xamoterol.]
[S01EA01, epinephrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Epinephrine.]
[N05CF02, zolpidem, Zolpidem may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX15, zonisamide, Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01BG01, moricizine, Moricizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G02AB03, ergonovine, Ergometrine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CA02, ergotamine, Ergotamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AG01, valproic acid, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA15, gepefrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Gepefrine.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Ipratropium.]
[N03AD01, ethosuximide, Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Etilefrine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A02BA04, nizatidine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Nizatidine.]
[R06AX12, terfenadine, The risk or severity of adverse effects can be increased when Terfenadine is combined with Ipratropium.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AB08, fluvoxamine, Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AX26, fenfluramine, Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Ipratropium is combined with Fentanyl.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Flavoxate is combined with Ipratropium.]
[N07CA03, flunarizine, Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA14, melitracen, Melitracen may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V03AZ01, ethanol, Ethanol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AB03, fluoxetine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AF01, flupenthixol, The risk or severity of adverse effects can be increased when Flupentixol is combined with Ipratropium.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AG01, fluspirilene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06BX17, adrafinil, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Adrafinil.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G01AX06, furazolidone, Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CF04, eszopiclone, Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AL05, amisulpride, Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DA04, galantamine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Galantamine.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA04, barbexaclone, Barbexaclone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BC06, cabergoline, Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AD03, methsuximide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Ipratropium is combined with Alfentanil.]
[H04AA01, glucagon, Ipratropium may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Ipratropium.]
[N05AD01, haloperidol, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Quetiapine is combined with Ipratropium.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Ipratropium.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Ipratropium.]
[N05CA16, hexobarbital, Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC05, hexoprenaline, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Hexoprenaline.]
[C03AA03, hydrochlorothiazide, The serum concentration of Hydrochlorothiazide can be increased when it is combined with Ipratropium.]
[R05DA03, hydrocodone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Hydrocodone.]
[C03AA02, hydroflumethiazide, The serum concentration of Hydroflumethiazide can be increased when it is combined with Ipratropium.]
[G04BD06, propiverine, The risk or severity of adverse effects can be increased when Propiverine is combined with Ipratropium.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02AC06, rilmenidine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Rilmenidine.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Ipratropium.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Ipratropium is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of adverse effects can be increased when Imipramine is combined with Ipratropium.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03BA11, indapamide, The serum concentration of Indapamide can be increased when it is combined with Ipratropium.]
[N06AX17, milnacipran, Milnacipran may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Piperidolate is combined with Ipratropium.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R06AE01, buclizine, The risk or severity of adverse effects can be increased when Buclizine is combined with Ipratropium.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Anagrelide is combined with Ipratropium.]
[C07AA01, alprenolol, Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03BA02, quinethazone, The serum concentration of Quinethazone can be increased when it is combined with Ipratropium.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AF05, iproniazid, Iproniazid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CC06, isoetharine, The risk or severity of Tachycardia can be increased when Isoetharine is combined with Ipratropium.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01EB07, isoflurophate, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03CB01, isoproterenol, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Isoprenaline.]
[C04AA01, isoxsuprine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Isoxsuprine.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Ipratropium.]
[C01CA22, arbutamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Arbutamine.]
[N04BC09, rotigotine, Rotigotine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C07AG01, labetalol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Amantadine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Ipratropium.]
[N07AA30, ambenonium, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ipratropium.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BA01, levodopa, The absorption of Levodopa can be decreased when combined with Ipratropium.]
[S02DA01, lidocaine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AH01, loxapine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Loxapine.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Ipratropium.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Ipratropium.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA21, maprotiline, The risk or severity of adverse effects can be increased when Maprotiline is combined with Ipratropium.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Mecamylamine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Ipratropium.]
[P01BC02, mefloquine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06DX01, memantine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Mephentermine.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Ipratropium is combined with Meptazinol.]
[N05AC03, mesoridazine, Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AX13, paliperidone, Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA09, metaraminol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Metaraminol.]
[A04AA04, dolasetron, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Methadone.]
[N06BA03, methamphetamine, Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Methantheline is combined with Ipratropium.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA15, methohexital, Methohexital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02BG08, ziconotide, Ziconotide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AA02, methotrimeprazine, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ipratropium.]
[C01CA10, methoxamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Methoxamine.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA08, methyclothiazide, The serum concentration of Methyclothiazide can be increased when it is combined with Ipratropium.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Ipratropium.]
[V04CG05, methylene blue, Methylene blue may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AF03, rufinamide, Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Ipratropium.]
[C03BA08, metolazone, The serum concentration of Metolazone can be increased when it is combined with Ipratropium.]
[N06AX03, mianserin, Mianserin may increase the anticholinergic activities of Ipratropium.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA17, midodrine, The risk or severity of Tachycardia can be increased when Midodrine is combined with Ipratropium.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Ipratropium.]
[N06BA12, lisdexamfetamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Lisdexamfetamine.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA09, amitriptyline, The risk or severity of adverse effects can be increased when Amitriptyline is combined with Ipratropium.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Morphine.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA02, amobarbital, Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07XX04, sodium oxybate, Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, The risk or severity of adverse effects can be increased when Amoxapine is combined with Ipratropium.]
[N03AB05, fosphenytoin, Fosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Nalbuphine.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Naltrexone.]
[S01GA01, naphazoline, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Ipratropium.]
[N06AX21, duloxetine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Ipratropium is combined with Remifentanil.]
[S01EB06, neostigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AF02, nialamide, Nialamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Nicardipine is combined with Ipratropium.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Ipratropium.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01CA03, norepinephrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Norepinephrine.]
[N06AA10, nortriptyline, The risk or severity of adverse effects can be increased when Nortriptyline is combined with Ipratropium.]
[G02CA02, nylidrin, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Nylidrin.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Ipratropium is combined with Opium.]
[R03CB03, metaproterenol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Orciprenaline.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C07AA02, oxprenolol, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The absorption of Ipratropium can be decreased when combined with Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Ipratropium is combined with Oxymorphone.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Ipratropium.]
[N05AH05, asenapine, Asenapine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AX06, tapentadol, The risk or severity of adverse effects can be increased when Ipratropium is combined with Tapentadol.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Ipratropium.]
[N05CC05, paraldehyde, Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02KC01, pargyline, Pargyline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Fesoterodine is combined with Ipratropium.]
[C07AA23, penbutolol, Penbutolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AG03, penfluridol, Penfluridol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Pentazocine.]
[N05CA01, pentobarbital, Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04BC02, pergolide, Pergolide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Phenazocine.]
[N06AF03, phenelzine, Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA02, phenobarbital, Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Ipratropium.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Ipratropium is combined with Phenoperidine.]
[A08AA01, phentermine, The risk or severity of Tachycardia can be increased when Phentermine is combined with Ipratropium.]
[S01GA05, phenylephrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Phenylephrine.]
[R01BA01, phenylpropanolamine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Phenylpropanolamine.]
[N03AB02, phenytoin, Phenytoin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V03AB19, physostigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Physostigmine.]
[N05AG02, pimozide, Pimozide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C07AA03, pindolol, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Pirenzepine is combined with Ipratropium.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Piritramide.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Pizotifen is combined with Ipratropium.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ipratropium.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C03AA05, polythiazide, The serum concentration of Polythiazide can be increased when it is combined with Ipratropium.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Ipratropium is combined with Potassium chloride.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N03AA03, primidone, Primidone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01BA02, procainamide, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Procainamide.]
[S01HA05, procaine, Procaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[L01XB01, procarbazine, Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Ipratropium.]
[N05AA03, promazine, The risk or severity of adverse effects can be increased when Promazine is combined with Ipratropium.]
[R06AD02, promethazine, The risk or severity of adverse effects can be increased when Promethazine is combined with Ipratropium.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Propantheline is combined with Ipratropium.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Ipratropium.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Ipratropium is combined with Dextropropoxyphene.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R01BA02, pseudoephedrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ipratropium.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Diphemanil is combined with Ipratropium.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Isopropamide is combined with Ipratropium.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Methscopolamine is combined with Ipratropium.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C01BA01, quinidine, The risk or severity of adverse effects can be increased when Quinidine is combined with Ipratropium.]
[P01BC01, quinine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[R03AC05, rimiterol, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Ritodrine.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Ipratropium.]
[N05CA06, secobarbital, Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Ipratropium.]
[N04BD01, selegiline, Selegiline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Ipratropium.]
